Core Viewpoint - Weisi Medical's performance showed steady growth in the first half of 2025, driven by a recovery in hospital procurement demand and the expansion of new business initiatives [2][3]. Financial Performance - In the first half of 2025, Weisi Medical achieved operating revenue of 210 million yuan, a year-on-year increase of 9.85% [2]. - The net profit attributable to shareholders was 69.32 million yuan, reflecting a year-on-year growth of 39.71% [2]. - The net profit excluding non-recurring gains and losses was 63.57 million yuan, up 46.30% year-on-year [2]. - The net cash flow from operating activities reached 64.78 million yuan, marking a significant increase of 101.53% [2]. Business Development - Weisi Medical focuses on high-end rehabilitation equipment across various fields, including pelvic and postpartum rehabilitation, neurological rehabilitation, mental rehabilitation, sports rehabilitation, and pediatric rehabilitation [2]. - The company launched a new generation of physical factor platforms, enhancing the competitiveness of pelvic electrical stimulation products [2]. - Future plans include deepening efforts in women's health and exploring new demands for lifecycle management, aiming to upgrade the pelvic market towards a comprehensive solution combining "pelvic rehabilitation + light medical beauty" [2]. Strategic Initiatives - Weisi Medical is accelerating its layout in laser technology through external acquisitions, establishing a competitive edge in the urology field [3]. - The company is focusing on the medical beauty energy source market, developing innovative products such as picosecond lasers and radiofrequency devices to align with international standards [3]. - Plans to enhance market share in core businesses like pelvic, neurological, and mental rehabilitation are underway, with a focus on clinical applications for products like transcranial magnetic stimulation devices in mental health [3]. Incentive Plans - Weisi Medical introduced a stock incentive plan for 2025-2026, with revenue growth as the sole assessment criterion, targeting an 18% and 40% increase in revenue for 2025 and 2026, respectively, compared to 2024 [4][5].